Patents Assigned to Universite de Montreal
  • Patent number: 11348572
    Abstract: A speech recognition method includes obtaining an acoustic sequence divided into a plurality of frames, and determining pronunciations in the acoustic sequence by predicting a duration of a same pronunciation in the acoustic sequence and skipping a pronunciation prediction for a frame corresponding to the duration.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 31, 2022
    Assignees: Samsung Electronics Co., Ltd., UNIVERSITE DE MONTREAL
    Inventors: Inchul Song, Junyoung Chung, Taesup Kim, Sanghyun Yoo
  • Publication number: 20220121040
    Abstract: A method for determining a design of a progressive lens intended to be worn by a future wearer, the progressive lens comprising a front surface and a back surface, at least one of the front surface and the back surface comprising a progression profile on its general spherical shape, said at least one progression profile defining a meridian line extending from a distance-vision point to a near-vision point, said meridian line comprising a vertical portion passing through the distance-vision point and an inclined portion passing through the near-vision point, the vertical portion and the inclined portion forming an angle between them, the method including obtaining first data representative of a first measurement of a first postural instability of the future wearer when seeing a visual pattern moving along an mediolateral direction, and determining a reparation between the first progression profile and the second progression profile based on the first data.
    Type: Application
    Filed: November 27, 2019
    Publication date: April 21, 2022
    Applicants: Essilor International, UNIVERSITE DE MONTREAL
    Inventors: Delphine TRANVOUEZ-BERNARDIN, Jocelyn FAUBERT, Guillaume GIRAUDET
  • Publication number: 20220026741
    Abstract: A method for determining a design of a progressive lens intended to be worn by a future wearer, the progressive lens comprising a front surface and a back surface, at least one of the front surface and the back surface comprising a progression profile on its general spherical shape, said at least one progression profile defining a meridian line extending from a distance-vision point to a near-vision point, said meridian line comprising a vertical portion passing through the distance-vision point and an inclined portion passing through the near-vision point, the vertical portion and the inclined portion forming an angle between them, the method comprising obtaining first data representative of a first measurement of a first postural instability of the future wearer when seeing at a visual pattern moving along an anterior-posterior direction, and determining the angle of the inclined portion based on the first data.
    Type: Application
    Filed: November 27, 2019
    Publication date: January 27, 2022
    Applicants: Essilor International, UNIVERSITE DE MONTREAL
    Inventors: Delphine TRANVOUEZ-BERNARDIN, Jocelyn FAUBERT, Guillaume GIRAUDET
  • Publication number: 20220011596
    Abstract: A system and method for determining an adapted ophthalmic device for a wearer, the method including acquiring a set of parameters values relating to the wearer, determining at least a task to be performed by the wearer involving visual exploration, using a computing system, determining a value of a criterion assessing an efficiency of the wearer's visual exploration strategy for the task, and determining an optical design of an ophthalmic device to be worn by a wearer according to the determined value of the criterion.
    Type: Application
    Filed: October 9, 2019
    Publication date: January 13, 2022
    Applicants: Essilor International, UNIVERSITE DE MONTREAL
    Inventors: Delphine BERNARDIN, Jocelyn FAUBERT, Romain CHAUMILLON, Eduardo LUGO, Sergio MEJIA ROMERO
  • Publication number: 20210322509
    Abstract: A method for preventing or reducing the risk of perinatal or neonatal morbidity and mortality caused by antenatal inflammation in humans is described. This method is based on the administration of a compound of formula I or a pharmaceutically acceptable salt thereof: to an expectant human mother suffering from antenatal fetal inflammation. The method prevents or reduces the risk of organ damages, including brain, lung and intestinal damages, and sequelae therefrom, in the neonates, as well as the risk of neonatal death.
    Type: Application
    Filed: June 30, 2021
    Publication date: October 21, 2021
    Applicants: CHU SAINTE-JUSTINE, UNIVERSITÉ DE MONTRÉAL, THE UNIVERSITY OF ADELAIDE
    Inventors: Sylvain CHEMTOB, Christiane QUINIOU, Sarah Anne ROBERTSON, Mathieu NADEAU-VALLÉE, William D. LUBELL, David OLSON, Peck Yin CHIN, Sylvie GIRARD, Doan-Ngoc DUC
  • Publication number: 20210261504
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: March 8, 2021
    Publication date: August 26, 2021
    Applicants: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee L. Edinger, Stephen Hanessian
  • Publication number: 20210261583
    Abstract: Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: June 14, 2019
    Publication date: August 26, 2021
    Applicants: The Regents of the University of California, Universite de Montreal
    Inventors: Aimee Edinger, Stephen Hanessian
  • Patent number: 11072616
    Abstract: There is described herein antagonists of ?4?7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and R8 are various substituents; stereocentres 1*, 2* and 3* are each independently selected from R and S; n is 1, 2, 3, or 4 and where n is 2-4, Z is an amino terminus of an amino acid; —C?O— adjacent L is the carboxy terminus of an amino acid; and L along with Z and —C?O— is a peptide.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 27, 2021
    Assignees: Universite de Montreal, Zealand Pharma A/S
    Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Adam Paul Kafal, James Gillard, Narendra Patel, Sai Kumar Chakka, Andrew L. Roughton, Marc-André Poupart, Gaoqiang Yang
  • Patent number: 11046695
    Abstract: There is described herein use of a compound of formula (I) below to make cyclic peptides.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: June 29, 2021
    Assignees: Zealand Pharma A/S, Universite de Montreal
    Inventors: Manuel Perez Vazquez, M. Monzur Morshed, Jennifer L. Hickey, Marc-André Poupart, Gaoqiang Yang, James Gillard, Adam Paul Kafal, Andrew L. Roughton
  • Patent number: 10954194
    Abstract: The invention relates to a method of treating a subject who has cancer or a non-malignant tumor, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: March 23, 2021
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/ McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Patent number: 10877036
    Abstract: Resonance energy transfer (RET)- or protein-fragment complement assay (PCA)-based biosensors useful for assessing the activity of G-proteins are described. These biosensors are based on the competition between the G? subunit and a G?? interacting protein (?? IP) for the binding to the G?? dimer. These biosensors comprises (1) a ?? IP and (2) a G? or G? protein; a GPCR; or a plasma membrane targeting domain, fused to suitable RET or PCA tags. Methods using such biosensors for different applications, including the identification of agents that modulates G-protein activity or for the characterization of GPCR signaling/regulation, such as G-protein preferences and activation profiles of GPCRs, are also described.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Michel Bouvier, Christian Le Gouill, Mireille Hogue, Viktoriya Lukasheva
  • Publication number: 20200348536
    Abstract: A method for determining an optical system intended to equip a person on the basis of the adaptability of the person to a visual and/or proprioceptive modification of his environment, the method.
    Type: Application
    Filed: August 30, 2018
    Publication date: November 5, 2020
    Applicants: Essilor International, Universite de Montreal
    Inventors: Guillaume GIRAUDET, Jocelyn FAUBERT, Rafael DOTI, Eduardo LUGO
  • Patent number: 10822343
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: November 3, 2020
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Publication number: 20200323923
    Abstract: The invention relates to compounds as described herein and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, an autoimmune disease and/or an inherited immunodeficient disease.
    Type: Application
    Filed: November 1, 2018
    Publication date: October 15, 2020
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Bruno SIMONEAU, Yves CHANTIGNY, Jonathan YEH, Guy SAUVAGEAU, Anne MARINIER
  • Patent number: 10792154
    Abstract: A limb sparring system for replacing a portion of a radius, the radius being adjacent to an ulna, the system comprising a cutting guide including a cut guiding portion for guiding a saw when making a predetermined cut in the radius to excise the portion of the radius, an opposed ulnar mounting portion mountable to the ulna, and a linking portion extending therebetween; and an endoprosthesis configured for replacing the portion of the radius after the portion of the radius has been excised. When the cutting guide is operatively mounted to the radius and ulna, the cut guiding portion and the ulnar mounting portion engage respectively the radius and the ulna in a predetermined spatial relationship relative thereto.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: October 6, 2020
    Assignees: SOCOVAR, L.P., Colorado State University Research Foundation, Universite de Montreal
    Inventors: Vladimir Brailovski, Yvan Petit, Bertrand Lussier, Bernard Seguin, Martin Brummund, Anatolie Timercan
  • Publication number: 20200306213
    Abstract: Compounds, compositions and their use in the treatment or prevention of symptoms of Lowe Syndrome and Dent disease 2 are described, for instance, the use of such compounds in the treatment of Lowe Syndrome and Dent disease 2, or in the treatment or prevention of at least one symptom associated therewith.
    Type: Application
    Filed: September 27, 2018
    Publication date: October 1, 2020
    Applicants: Université de Montréal, The University of Manchester, Centre National De La Recherche Scientifique, Sorbonne Université, Institut Pasteur
    Inventors: Sébastien CARRENO, Khaled Ben El Kadhi, Arnaud Echard, Clothilde Cauvin, Martin Lowe
  • Patent number: 10752591
    Abstract: The invention relates to a method of inhibiting loss of muscle mass or muscle function in a subject in need thereof, or a method of treating miofibers ex vivo, the method comprising administering a therapeutically effective amount of a 18-20 member bi-polycyclic compound to the subject or to the miofibers.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 25, 2020
    Assignees: Haro Pharmaceuticals Inc., The Royal Institution for the Advancement of Learning/McGill University, Universite De Montreal
    Inventors: David Bettoun, Eduardo Martinez, James Gleason, Sylvie Mader, Shuo Xing
  • Publication number: 20200214926
    Abstract: The application relates to a method for adapting the visual and/or visual-motor behavior of a person, including: providing an optical parameter and a person visual parameter; providing a target value; modifying a visual and/or visual motor behavior; assessing a person visual parameter; determining a suitable visual and/or visual-motor behavior; and adapting the visual and/or visual-motor behavior of the person.
    Type: Application
    Filed: October 2, 2018
    Publication date: July 9, 2020
    Applicants: Essilor International, Universite de Montreal
    Inventors: Bjorn DROBE, Jocelyn FAUBERT, Guillaume GIRAUDET
  • Publication number: 20200188361
    Abstract: A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need thereof an effective amount of a mitochondrial activity inhibitor, for example a class A electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDII1, mutated IDII2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.
    Type: Application
    Filed: January 24, 2020
    Publication date: June 18, 2020
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Irene Baccelli
  • Publication number: 20200126534
    Abstract: A speech recognition method and apparatus, including implementation and/or training, are disclosed. The speech recognition method includes obtaining a speech signal, and performing a recognition of the speech signal, including generating a dialect parameter, for the speech signal, from input dialect data using a parameter generation model, applying the dialect parameter to a trained speech recognition model to generate a dialect speech recognition model, and generating a speech recognition result from the speech signal by implementing, with respect to the speech signal, the dialect speech recognition model. The speech recognition method and apparatus may perform speech recognition and/or training of the speech recognition model and the parameter generation model.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 23, 2020
    Applicants: Samsung Electronics Co., Ltd., Universite De Montreal
    Inventors: Sanghyun YOO, Yoshua BENGIO, Inchul SONG